CMS’ GLP-1 Bridge Demonstration | ClinicLens

This Viewpoint discusses the US Centers for Medicare & Medicaid Services’ (CMS) extension of the Medicare Glucagon-Like Peptide-1 (GLP-1) Bridge and outlines unanswered questions related to how the bridge will affect Medicare.

Medical Literature · Updated 2026-08-02

← Back to articles

This standalone article is served from the ClinicLens content archive.

If the embedded page does not load in your browser, open it directly.